Chemed vs Natera
Chemed reported revenue of $2.5 billion in fiscal 2025, about the same as Natera's $2.3 billion in fiscal 2025. Chemed's revenue grew 4.1% in its latest year, and Natera's grew 35.9%. Chemed had an operating margin of 13.4%, against -13.4% at Natera. Free cash flow was $325 million at Chemed and $109 million at Natera.
Side by side
| Chemed | Natera | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2.5B | $2.3B |
| Revenue growth | 4.1% | 35.9% |
| Revenue growth a year, last 5 years | 4.0% | 42.6% |
| Gross margin | 32.5% | — |
| Operating margin | 13.4% | −13.4% |
| Net margin | 10.5% | −9.0% |
| Free cash flow | $325M | $109M |
| Free cash flow margin | 12.9% | 4.7% |
| Return on capital | 27.3% | — |
| Net debt to EBITDA | −0.2x | — |
| Dividends and buybacks | $463M | $0M |
| Change in diluted share count | −4.8% | 9.6% |
| Last close | $512.90 | $404.90 |
| P/E at the last close | 25.8× | — |
| Insider trades, last 12 months | sold $8.8 million | sold $373.9 million |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ChemedNatera
Operating margin
Percent of revenue
ChemedNatera
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ChemedNatera